StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for ESPR yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $3.12 | $3.12 | +0.00% | 8.1M |
| 05-18 | $3.12 | $3.13 | +0.32% | 12.4M |
| 05-19 | $3.14 | $3.13 | -0.32% | 7.0M |
| 05-20 | $3.13 | $3.13 | +0.00% | 7.8M |
| 05-21 | $3.13 | $3.13 | +0.16% | 3.3M |
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $80.10M | $403.13M | $234.69M | $147.38M |
Operating Income | $-6.58M | $60.27M | $-24.96M | $-15.00M |
Net Income | $-25.20M | $-22.68M | $-84.51M | $-12.72M |
EPS (Diluted) | $-0.10 | $-0.11 | $-0.43 | $-0.27 |
Total Assets | $462.53M | $465.89M | $364.02M | $347.08M |
Total Liabilities | $770.46M | $767.85M | $815.38M | $780.59M |
Cash & Equivalents | $156.16M | $167.85M | $92.45M | $86.06M |
Free Cash Flow OCF − CapEx | $-27.91M | $-13.09M | $-58.34M | $-54.05M |
Shares Outstanding | 251.35M | 207.87M | 198.15M | 196.84M |